Abstract: Objective To observe the effects of Niaoduqing on residual renal function in patients undergoing peritoneal dialysis and expression of vascular endothelial growth factor (VEGF).Methods Sixty patients undergoing peritoneal dialysis regularly were divided into treatment group(n = 30)and control group(n = 30).The patients of treatment group received Niaoduqing orally for three months,and those of control group did not receive.All patients were provided routine treatment of renal anemia and CAPD.The KT/V,RRF,urinary volume(UV). Ultrafitration(UF)and VEGF changes in two groups were observed.Results UV,KT/V and RRF of treatment group decreased,but UF increased after treatment as compared with before treatment,the differences were significant(P <0.05).The decreases of treatment group were more in degree compared with those of control group(P <0.01).The expression of VEGF in serum and peritoneal dialysate of treatment group decreased significantly after treatment as compared with before treatment(P <0.05).The expression of VEGF in serum and peritoneal dialysate of control group showed no significant change before and after treatment.Conclusion Niaoduqing can protect the renal function in patients undergoing peritoneal dialysis,reduce the toxin,and inhibit VEGF expression.

Key words: continuous ambulatory peritoneal dialysis, vascular endothelial growth factor, Niaoduqing